Lukas Delbert Wartman MD

Hematologic Oncology

Instructor, Internal Medicine, Washington University School of Medicine

4921 Parkview Pl# DvSt. Louis, MO 63110
Phone+1 800-647-2098
Fax+1 314-362-3192

Dr. Wartman is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wartman's full profile Already have an account?

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2007 - 2011
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2005 - 2007
WashU MedicineClass of 2005

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MO State Medical License 2007 - 2027
IL State Medical License 2019 - 2023

Clinical Trials

Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Start of enrollment: 2014 Aug 11
TERMINATED
PHASE1, PHASE2
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma Start of enrollment: 2014 Mar 19
COMPLETED
PHASE2
Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma Start of enrollment: 2015 Feb 20
COMPLETED
PHASE1

Publications & Presentations

PubMed

Exome sequencing of Hodgkin and non-Hodgkin composite lymphomas identifies shared somatic mutations indicative of common founding precursors.
Felicia Gomez, Lauren Shea, Sivasankar Annamalai Sharavanan, David Russler-Germain, Matthew Mosior
Cancer Genetics. 2026-06-01
6 citations
Combined Kdm6a and Trp53 Deficiency Drives the Development of Squamous Cell Skin Cancer in Mice.
Lauren K Shea, Neal S Akhave, Leslie A Sutton, Leigh A Compton, Conner York
The Journal of Investigative Dermatology. 2023-02-01
15 citations
Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma.
Erica K Barnell, Zachary L Skidmore, Kenneth F Newcomer, Monique Chavez, Katie M Campbell
Blood Advances. 2023-01-24

Journal Articles

Exome Analysis of Treatment‐Related AML After APL Suggests Secondary Evolution
John S Welch, Eric J Duncavage, Meagan A Jacoby, Peter Westervelt, Lukas D Wartman, British Journal of Haematology

Press Mentions

GVHD Alliance to Honor Steven Pavletic with the Inaugural Lukas D. Wartman GVHD Achievement AwardFebruary 16th, 2023
Interview with A Hematologist: 'I’m a Leukemia Doctor, a Leukemia Researcher, and a Leukemia Patient'April 1st, 2019
IBM's ‘Dr. Watson’ Has yet to Show It Can Improve Patient Outcomes or Accurately Diagnose CancerSeptember 21st, 2018